-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) occurs due to clonal proliferation of malignant plasma cells in the bone marrow and/or extramedullary sites, and there is an unmet need for the treatment of patients with drug-resistant/refractory multiple myeloma (MM)
Multiple myeloma (MM) occurs due to clonal proliferation of malignant plasma cells in the bone marrow and/or extramedullary sites, and there is an unmet need for the treatment of patients with drug-resistant/refractory multiple myeloma (MM)
The researchers recruited 28 patients between February 2020 and December 2021
Figure 1: Schematic diagram of patient placement
Figure 1: Schematic diagram of patient placement
Table 1: Response to PBD treatment
Table 1: Response to PBD treatment
Patients received a median of 3 previous medications, and 85.
Figure 2: (A) Progression-free survival (n = 28)
Figure 2: (A) Progression-free survival (n = 28)
Table 2: Dose reductions and discontinuations
Table 2: Dose reductions and discontinuations
An ORR of 57.
The study suggests that bendamustine, pomalidomide, and dexamethasone may be a new combination for the treatment of heavily pretreated lenalidomide-refractory myeloma populations
Original source:
Original source:Kumar, S ,Sharma, A ,Malik, PS , Gogia, A , Pathak, N , Sahoo, RK , et al.
Kumar, S , Sharma, A , Malik, PS , Gogia, A , Pathak, N , Sahoo, RK , et al.
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial .
Br J Haematol .
2022 ; 00 : 1 – 10 .
https://doi.
org/10.
1111/bjh.
18200.
Kumar, S Sharma, A Malik, PS Gogia, A Pathak, N Sahoo, RK Bendamustine in combination with pomalidomide and dexamethasone in relapsed/ refractory multiple myeloma: A phase II trialBr J Haematol 2022 00 1 10
Leave a comment here
